Speakers

Dr. Alugupalli discovered the function of B1b cells, a subset of B lymphocytes that can generate long-lasting immunity. This discovery led to the identification for pathways and parameters crucial for immunological memory, a key aspect for making effective and safe subunit vaccines that can provide durable immunity.

In 2005, he accepted a tenure-track faculty position in the department of Microbiology and immunology, Thomas Jefferson University, Philadelphia. At the Thomas Jefferson University he served as the Director of the Immunology and Microbial Pathogenesis PhD program and became the Immunology Director of the PharmD program at the Jefferson College of Pharmacy. His 20 years of academic research was continuously funded by the National Institutes of Health. With a focused goal of making efficient and cost-effective bacterial subunit vaccines, in 2023 Dr. Alugupalli founded TurboVax Inc, a Delaware C-corporation and left academia and became the full-time CEO of TurboVax Inc to dedicate his time on a goal to minimize the threat of antimicrobial resistance, and the reduce bacterial disease burden globally. TurboVax Inc is interested in commercialization of an indispensable and path-breaking vaccine adjuvant named Turbo for glycoconjugate subunit vaccines. Bacterial polysaccharide or glycoconjugate subunit vaccines when adjuvanted with Turbo induces long-lasting and highly protective immune responses across all ages and eliminates the need for boosters. By partnering with Vaccine developers, TurboVax Inc will help prevent a wide range of bacterial infections.